I
n Canada, late-life depression is a serious public health problem. A recent Canadian survey shows that 6.7% and 19% of the general elderly population has major depression or depressive symptoms, respectively. 1 Because depressive disorders in elderly individuals are associated with elevated risks for impaired physical and emotional health, 2,3 pain, 4 loss of productivity, 2 nursing home admission, 5 and mortality from medical conditions 6, 7 and suicide, 2 delivery of effective treatment is essential to improving both quality and length of life.
Canadian guidelines were developed to assist practitioners with diagnosis and treatment of depression. According to these guidelines, ADs are the recommended pharmacotherapies for major depression, 8 and lithium, divalproex, and some atypical antipsychotics are the recommended pharmacotherapies for bipolar disorder. 9 According to the Canadian Study of Health and Aging, use of ADs is similar across Canadian provinces (ranging from 10% to 16%), although benzodiazepine use is significantly higher in Quebec, compared with the Atlantic and Prairie provinces (36% and 18%, respectively; P = 0.02). 10 However, suboptimal AD treatment of depression is consistently reported. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Suboptimal medication regimens are those in which either the medication, dosage, or duration of treatment are not consistent with published guidelines. For example, in Pennsylvania, 43% of newly diagnosed depressed elderly individuals enrolled in the largest state prescription benefits program were taking suboptimal medication regimens. 18 Early discontinuation is reported in the United States: only 36% of elderly patients diagnosed with depression receive adequate dosages of ADs for more than 90 days 23 and up to 41% discontinue medication during the first month of treatment. 24 Similarly, in Canada, data from Quebec and Nova Scotia show that about 45% and 47%, respectively, of elderly individuals discontinue ADs before 180 days. 13, 15 These findings are disturbing because elderly individuals with first-episode major depression are at risk for recurrence following discontinuation of maintenance ADs. 25 Because many of these studies employed data that are more than 10 years old, there is clearly a need to reevaluate treatment of late-life depression in a more current context.
A timely opportunity exists to evaluate use of psychoactive medication for mental health problems by elderly Canadians using the data from the CCHS 1.2. 26 This survey gathered information on depressive symptoms, psychoactive medication use (sleep aids, anxiolytics, and mood stabilizers and [or] ADs), and nonadherence. Thus our research aims were to describe the psychoactive medications taken by community-dwelling elderly individuals and to evaluate the impact of depression both on psychoactive medications used to treat late-life depression and on psychoactive medication nonadherence. Given that depressive symptoms in the absence of depressive disorder are associated with poor outcomes, 27 we also examined psychoactive medication use by seniors with depressive symptoms.
Methods
We employed data from the CCHS First, households were selected according to a multistage stratified cluster design. Then, one individual per household was selected to respond to the survey according to a strategy that assured overrepresentation of young and elderly individuals. The selected respondent was asked for verbal informed consent to participate. Nonresponse was minimized by the use of introductory letters, multiple contacts, and follow-up information for individuals who initially refused. Interviews were conducted in several languages. These survey methods led to a response rate of 77%. Face-to-face interviews were employed where possible, although about 14% of interviews were conducted by telephone. Data quality was monitored in the field, and computer-assisted interviewing was employed.
Data assessed included sociodemographics, 36 chronic medical conditions, lifetime and previous-year occurrences of mental health disorders (for example, major depression and mania), health services use, and medication use. Psychoactive medication use was determined by 4 self-report questions pertaining to the use of mood stabilizers and ADs, medication to reduce anxiety or nervousness, and medication to aid sleep in the past 12 months. Information on psychoactive medication use in the 2 days prior to the interview was also assessed by examination of pill bottles to determine the names of the medications.
Depression Classification
In the survey, a Canadian adaptation of the CIDI was used to assess psychiatric disorder. 28 Previous versions of the CIDI demonstrated satisfactory reliability and validity. 29 The CCHS 1.2 CIDI assessed major depression during the past 12 months, and provided information on the number of previous episodes. Manic episodes, 3 common anxiety disorders (that is, panic disorder, agoraphobia, and social phobia), alcohol abuse, drug abuse, and problem gambling were also evaluated. Information obtained from the CIDI was used to define the depression categories.
The DSM-IV criteria 30 for major depression include:
A. 5 or more symptoms of depression (depressed mood, loss of interest, weight loss, psychomotor disturbance, sleep disturbance, fatigue, feelings of worthlessness, decreased concentration, and recurrent thoughts of death or suicide) present for at least 2 weeks, of which one is either depressed mood or loss of interest;
B. symptoms do not meet criteria for a mixed episode;
C. clinically significant distress or impairment;
D. symptoms not owing to substance abuse or medical illness; and E. symptoms not owing to bereavement.
Given the controversy regarding the sensitivity of formal diagnostic criteria among community-dwelling seniors, and our wanting to capture depression occurring in the context of comorbid illness, we created 4 mutually exclusive categories of depression based on information reported in the survey: major depression, comorbid major depression (major depression occurring in the context of physical illness, based on self-report that depression was related to physical illness, substance abuse, or bereavement), depressive symptoms (not meeting criteria for major depression), and no depressive symptoms. To examine the effect of depression severity on medication use and nonadherence, criterion C (clinically significant distress or impairment) was not applied to the first 3 categories above but added to the analysis as an independent variable. . Psychoactive medication nonadherence was defined as a positive response to the survey item that followed use of each type of psychoactive medication ("Were there any days when you either forgot to take the medicine or took less than you were supposed to take?").
Statistical Analyses
Descriptive statistics were used to characterize the study sample. Multiple logistic regression was employed to identify the independent correlates of the binary variables, including use of sleep aids, anxiolytics, mood stabilizers and (or) ADs, and any psychoactive medication, and medication nonadherence. To maintain confidentiality and to allow for generalization to the Canadian population, only weighted responses are reported, as required by Statistics Canada. Weights were provided by Statistics Canada. Missing data were treated as a separate category for the purpose of generating descriptive statistics. For other analyses, missing data were imputed by the majority rule. Given the numerous statistically significant associations, only ORs of 0.7 or less and of 1.5 or more will be discussed. Although interaction terms were created between the depression categories and other variables to identify the variables associated with psychoactive medication use by depressed seniors, none were found to be statistically significant (P = 0.10).
Ethical approval from the Research Ethics Committee of St Mary's Hospital Centre and permission from Statistics Canada were obtained prior to study inception. All analyses were carried out using Statistic Analysis Software (SAS, Version 9.1, 2004, Cary, NC) at the Quebec Inter-University Centre for Social Statistics, which provided access to the CCHS 1.2 data. Table 1 presents the characteristics of the 7736 elderly survey respondents. Most were aged 74 years and younger, female, married, English-speaking, and in good-to-excellent health. Most respondents resided in urban areas, were born outside of Canada, had little activity limitation, had at least 4 close friends or relatives, and reported that religion was important Among respondents who consulted with health care professionals, a majority of those treated by psychiatrists and family physicians took psychoactive medication in the preceding 12 months. However, only a minority of those taking psychoactive medication consulted a health professional for a mental health problem during the previous 12 months. Table 3 presents the results of the stepwise multivariate analyses for the study outcomes. The independent variables associated with use of sleep aids included: the 3 depression categories, aged 84 years or older, female, having fair or poor health, moderate-to-severe depression, having a chronic condition, and consulting a family physician. Significant correlates of anxiolytic use included: the 3 depression categories, female, French-speaking, all regions other than British Columbia, having fair or poor health, having another mental disorder, having a chronic condition, consulting a family physician, and all income categories below the highest. Variables that were independently correlated with use of mood stabilizers and (or) ADs included: major depression and depressive symptoms, female, being married, separated, divorced, or widowed, English-speaking, urban residence, fair or poor health, consulting a psychiatrist or family doctor, and having 2 or more previous depressive episodes. The independent correlates of use of any psychoactive medication included: the 3 depression categories, female, fair to poor health, moderate-to-severe depression, chronic medical condition, and consulting with a psychiatrist or family doctor. In the stepwise multiple logistic regression model for medication nonadherence, having depressive symptoms in the previous 2 weeks, French-speaking, mild depression, and consulting with a family physician were identified as independent correlates of nonadherence.
Results

Discussion
We used data from the CCHS These results imply not only that sleep aids can be used to manage late-life depression but also that elderly individuals with depression or depressive symptoms may be self-medicating with over-the-counter drugs, especially given that few had consulted a health professional for mental health problems in the previous year. Even among those taking anxiolytics and ADs and (or) mood stabilizers, few had consulted health care professionals; respondents might have received these prescription medications at visits for which they did not seek care for mental health problems or the medications might have been given for disorders other than depression. 20 Because mood stabilizers and (or) ADs may be effective for comorbid major depression, it is disturbing that elderly individuals with comorbid major depression were less likely to take these medications, compared with sleep aids and anxiolytics. Depression severity appeared to influence use of mood stabilizers and (or) ADs as use was highest among respondents who were treated by psychiatrists and by those with 2 or more previous depressive episodes. Thus family physicians may want to ask their elderly patients about possible mental health problems during routine visits and provide medication advice accordingly.
Our findings underscore the reliance on psychoactive medication in the treatment both of comorbid major depression and of depressive symptoms. Indeed, use rates of sleep aids and anxiolytics were higher in these 2 depression categories, compared with major depression. Use rates of the 3 types of psychoactive medications were also about twice as high in the depressive symptoms subgroup, compared with those without depressive symptoms. These findings highlight the The overall rate of nonadherence to psychoactive medication in elderly individuals was around 30% and was only slightly higher among individuals with major depression and comorbid major depression. In comparison, the nonadherence rate was highest for those with depressive symptoms. Similar associations between greater disease severity and increased adherence to medication were found in other chronic disease populations. 36 Other characteristics that influence psychoactive medication nonadherence included younger age, females, single, French-speaking, Quebec resident, low education, comorbidity, consultation with a family doctor or other health care professional, and household income (upper-middle income category). After controlling for confounding variables, seniors with depressive symptoms were 60% more likely not to adhere to psychoactive medication, compared with those without depressive symptoms, possibly because those without depressive symptoms were taking these medications for sleep or mental health problems that were unrelated to depression or because their depressive symptoms improved in response to taking medication. Alternatively, elderly individuals with more severe depression were more likely to take medication as recommended, compared with those with depressive symptoms. Further research is required to determine why French-speaking individuals adhered less to psychoactive medication, compared with English-speaking individuals.
Elderly individuals who consulted a family physician were more likely to take sleep aids, anxiolytics, and mood stabilizers and (or) ADs, and not to adhere to medication. Although these data cannot address whether such medications are being appropriately prescribed or recommended, the findings imply that when an elderly patient sees a family doctor for a mental health problem the likely result is that the patient will be offered a psychoactive medication and, when this occurs, the patient responds by not taking the medication as recommended. In contrast, consultation with a psychiatrist was associated with increased odds for receiving a mood stabilizer and (or) an AD but not for medication nonadherence. Characteristics that are particular to either or both of the patient populations and of the physician practice behaviours (family medicine physicians or psychiatrists) may contribute to nonadherence to psychoactive medication.
Prevalence of major depression was higher in our study, compared with those of others, 34 perhaps because we evaluated depression in the previous 12 months whereas others evaluated current depression. However, our finding on the use rate of mood stabilizers and (or) ADs in depressed patients is lower than that found in the United States, where nearly 36% of depressed elderly individuals were taking ADs. 34 Some of our findings corroborated those of others that showed: use of AD is higher for those in urban areas, 37 depression prevalence is higher in women than in men, 34 and benzodiazepine use for depression is high. 34 Because social support was protective for anxiolytic use, there may be benefits to adopting a community approach to improving the Chi-square tests were used for all analyses; however, Fisher's exact tests were used when the expected cell number was small. 
Conclusions
This population-based survey provides current evidence for the suboptimal treatment of late-life depression by showing that about 20% of elderly Canadians with major depression had taken mood stabilizers and (or) ADs in the previous 12 months. Suboptimal treatment was more common among unmarried women living in rural areas who had not visited a family physician or psychiatrist. The good news is that major depression was not associated with increased psychoactive medication nonadherence given the increased risk for relapse in elderly individuals who prematurely discontinue treatment. 25, 38 Nonadherence to psychoactive medication was problematic for elderly individuals with depressive symptoms who were more likely to take mood stabilizers and (or) ADs, compared with other psychoactive medications. However, as there is little evidence for the effectiveness of ADs for depressive symptoms, physicians should not encourage patients to take such medications; patient nonadherence may, in fact, be the appropriate response. Of importance, few depressed elderly individuals taking psychoactive medication were seen by health practitioners for a mental health problem, implying that family physicians should use routine office visits to probe elderly patients for symptoms of depression to reassess medication needs.
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Résumé : L'utilisation de médicaments et la non-observance des médicaments psychotropes pour des problèmes de santé mentale par les personnes âgées des collectivités canadiennes souffrant de dépression Objectifs : Déterminer la relation entre le niveau de dépression et l'utilisation et la non-observance des médicaments psychotropes chez les personnes âgées canadiennes, étant donné que la dépression de fin de vie est un problème de santé mentale grave et répandu au Canada.
Méthodes : Les répondants de 65 ans et plus (n = 7 736) de l'Enquête sur la santé dans les collectivités canadiennes : santé mentale et bien-être composaient l'échantillon de l'étude. Les symptômes dépressifs ayant été évalués à l'aide de l'Entrevue diagnostique composite internationale (CIDI), nous avons créé 4 niveaux de dépression pour établir un spectre de troubles et (ou) de symptômes dépressifs : la dépression majeure, la dépression majeure comorbide, les symptômes dépressifs, et l'absence de symptômes dépressifs. Les médicaments psychotropes évalués comprenaient les somnifères, les anxiolytiques, les psychorégulateurs et (ou) les antidépresseurs. La non-observance a été définie comme étant soit ne pas prendre le médicament tel que recommandé, soit prendre le médicament à une dose plus faible que celle prescrite.
Résultats : En tout, 22,5 % des répondants ont pris un médicament psychotrope pour un problème de santé mentale dans les 12 mois précédents. L'utilisation de médicaments psychotropes était de 46,8 % pour la dépression majeure, de 43,1 % pour la dépression majeure comorbide, de 34,0 % pour les symptômes dépressifs, et de 17,6 % pour l'absence de symptômes dépressifs. Les taux d'utilisation de médicaments psychotropes allaient de 46,5 % de ceux souffrant de dépression majeure à 17,6 % de ceux sans symptômes dépressifs. Globalement, le taux de non-observance des médicaments psychotropes était de 31 %; les taux étaient les plus élevés chez ceux présentant des symptômes dépressifs (37,4 %) et les plus faibles chez les personnes sans symptômes dépressifs (27,4 %). Les 3 catégories dépressives étaient associées à de plus fortes probabilités d'utilisation et de non-observance.
Conclusion :
Les 3 catégories dépressives étaient associées à une utilisation et à une non-observance accrues des médicaments psychotropes; cependant, les taux d'utilisation des antidépresseurs et (ou) des psychorégulateurs pour la dépression cliniquement significative étaient faibles.
